- Email: [email protected]
A prospective, randomized trial evaluating the efficacy of two different hemostatic sealant in tubeless percutaneous nephrolithotomy
32nd Annual EAU Congress, 24-28 March 2017, London, United Kingdom
557
A prospective, randomized trial evaluating the efficacy of two different hemostatic sealant in tubeless percutaneous nephrolithotomy Eur Urol Suppl 2017; 16(3);e966
Kim S.H.2, Yoon B.I.3, Choi Y.S.1, Kim K-S.1, Lee K-W.1, Choi S.W.1, Bae W.J.1, Ha U-S.1, Lee J-Y.1, Kim S-W.1, Hong S-H.1, Cho H.J.1 1
The Catholic University of Korea, Seoul St. Mary's Hospital, Dept. of Urology, Seoul, South Korea, 2The Catholic University of Korea, St. Paul’s Hospital, Dept. of Urology, Seoul, South Korea, 3Catholic Kwandong University, International St. Mary’s Hospital, Dept. of Urology, Incheon, South Korea INTRODUCTION & OBJECTIVES: We performed a prospective, randomized trial to assess the safety and efficacy of Tisseel®, Tachosil® in tubeless percutaneous nephrolithotomy. MATERIAL & METHODS: A total of 75 patients undergoing tubeless percutaneous nephrolithotomy were randomized to receive Tisseel® (group 1), Tachosil® (group 2) and control (group 3) at the end of the procedure. The hemostatic sealants were placed under direct vision in the nephrostomy tract. The three groups were comparable in age, sex, height, weight, body mass index, stone size and in metabolic and anatomic features. (Table 1) Factors evaluated included postoperative blood loss, postoperative pain, hospital stay and perirenal hematoma formation. RESULTS: There was no difference in the hemoglobin, hematocrit decrease and blood transfusion requirements among the 3 groups. (Table 1) There was no significant difference in the extent of postoperative perirenal hematoma formation. (p=0.694) (Table 2) The average visual analog scale pain score on postoperative 1 day were 1.92±2.47, 1.72±1.67 and 1.48±1.73 respectively in each group. (p=0.378) The hospital stay were 2.28±0.93, 2.00±0.96, and 2.04±0.99 (p=0.579) in each group. No longterm sequelae were observed in the median follow up period of 24 months in any patient.
Eur Urol Suppl 2017; 16(3);e966
32nd Annual EAU Congress, 24-28 March 2017, London, United Kingdom
557
A prospective, randomized trial evaluating the efficacy of two different hemostatic sealant in tubeless percutaneous nephrolithotomy Eur Urol Suppl 2017; 16(3);e967
CONCLUSIONS: This study indicates that the hemostatic agents in standard tubeless PCNL were not expected to be effective or mandatory. Additional wide, prospective, randomized studies are required to get more fine clinical evidence for the hemostatic agent usage in tubeless PCNL.
Eur Urol Suppl 2017; 16(3);e967 Powered by TCPDF (www.tcpdf.org)
557
A prospective, randomized trial evaluating the efficacy of two different hemostatic sealant in tubeless percutaneous nephrolithotomy Eur Urol Suppl 2017; 16(3);e966
Kim S.H.2, Yoon B.I.3, Choi Y.S.1, Kim K-S.1, Lee K-W.1, Choi S.W.1, Bae W.J.1, Ha U-S.1, Lee J-Y.1, Kim S-W.1, Hong S-H.1, Cho H.J.1 1
The Catholic University of Korea, Seoul St. Mary's Hospital, Dept. of Urology, Seoul, South Korea, 2The Catholic University of Korea, St. Paul’s Hospital, Dept. of Urology, Seoul, South Korea, 3Catholic Kwandong University, International St. Mary’s Hospital, Dept. of Urology, Incheon, South Korea INTRODUCTION & OBJECTIVES: We performed a prospective, randomized trial to assess the safety and efficacy of Tisseel®, Tachosil® in tubeless percutaneous nephrolithotomy. MATERIAL & METHODS: A total of 75 patients undergoing tubeless percutaneous nephrolithotomy were randomized to receive Tisseel® (group 1), Tachosil® (group 2) and control (group 3) at the end of the procedure. The hemostatic sealants were placed under direct vision in the nephrostomy tract. The three groups were comparable in age, sex, height, weight, body mass index, stone size and in metabolic and anatomic features. (Table 1) Factors evaluated included postoperative blood loss, postoperative pain, hospital stay and perirenal hematoma formation. RESULTS: There was no difference in the hemoglobin, hematocrit decrease and blood transfusion requirements among the 3 groups. (Table 1) There was no significant difference in the extent of postoperative perirenal hematoma formation. (p=0.694) (Table 2) The average visual analog scale pain score on postoperative 1 day were 1.92±2.47, 1.72±1.67 and 1.48±1.73 respectively in each group. (p=0.378) The hospital stay were 2.28±0.93, 2.00±0.96, and 2.04±0.99 (p=0.579) in each group. No longterm sequelae were observed in the median follow up period of 24 months in any patient.
Eur Urol Suppl 2017; 16(3);e966
32nd Annual EAU Congress, 24-28 March 2017, London, United Kingdom
557
A prospective, randomized trial evaluating the efficacy of two different hemostatic sealant in tubeless percutaneous nephrolithotomy Eur Urol Suppl 2017; 16(3);e967
CONCLUSIONS: This study indicates that the hemostatic agents in standard tubeless PCNL were not expected to be effective or mandatory. Additional wide, prospective, randomized studies are required to get more fine clinical evidence for the hemostatic agent usage in tubeless PCNL.
Eur Urol Suppl 2017; 16(3);e967 Powered by TCPDF (www.tcpdf.org)